Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SGN-B6A |
| Synonyms | |
| Therapy Description |
SGN-B6A is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting integrin beta-6 linked to monomethyl auristatin E, which delivers the anti-microtubule agent to integrin beta-6-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37619980). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SGN-B6A | SGN B6A|SGNB6A|anti-integrin beta-6/MMAE ADC SGN-B6A|Sigvotatug vedotin | SGN-B6A is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting integrin beta-6 linked to monomethyl auristatin E, which delivers the anti-microtubule agent to integrin beta-6-expressing tumor cells, potentially resulting in inhibition of tumor growth (PMID: 37619980). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04389632 | Phase I | SGN-B6A | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CHE | 2 |
| NCT06012435 | Phase III | SGN-B6A Docetaxel | A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |